WO2010024108A1 - インフルエンザウイルス感染症の予防ないし治療剤 - Google Patents
インフルエンザウイルス感染症の予防ないし治療剤 Download PDFInfo
- Publication number
- WO2010024108A1 WO2010024108A1 PCT/JP2009/064012 JP2009064012W WO2010024108A1 WO 2010024108 A1 WO2010024108 A1 WO 2010024108A1 JP 2009064012 W JP2009064012 W JP 2009064012W WO 2010024108 A1 WO2010024108 A1 WO 2010024108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- unsubstituted
- self
- influenza virus
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a substance having an action of preventing or treating influenza virus infection (influenza), and a preventive or therapeutic agent for influenza virus infection.
- the present invention also relates to a method for preventing or treating influenza virus infection (influenza).
- HA hemagglutinin
- NA neuraminidase
- hemagglutinin involved in the first step of influenza virus infection, based on the diversity of the amino acid sequences of the antigen-determining regions (AE) that are extremely susceptible to mutation.
- AE antigen-determining regions
- the amino acid sequence difference between hemagglutinin subtypes ranges from 25 to 75%, the so-called receptor binding pocket region that binds to the host cell receptor is relatively unmutated and its three-dimensional structure is well conserved.
- Patent Document 1 describes a peptide for preventing infection with influenza virus, particularly a liposome preparation, and confirms the effect of the liposome preparation in vitro.
- FIG. 1 of Patent Document 2 shows that the H3G-1 peptide has an inhibitory effect on both H1N1 and H3N2, but its action was weak.
- An object of the present invention is to provide a substance having a high effect of preventing or treating influenza virus infection (influenza).
- Another object of the present invention is to provide a preventive or therapeutic agent for influenza virus.
- an object of the present invention is to provide a method for preventing or treating influenza virus.
- the present inventor further examined the anti-influenza virus action of the stearoylated peptide of SEQ ID NO: 1, and the peptide has an anti-influenza virus action only on H3N2 in the liposome preparation, but the H1 subtype in the self-assembly. It was found to be more effective against a wide range of influenza viruses including H3, H5, and H7 subtypes. Furthermore, it has been found that a peptide self-assembly can be obtained by acylating the N-terminus of the peptide with an acyl group having 14 to 24 carbon atoms.
- the present invention provides the following self-assembly and preventive or therapeutic agent for influenza virus infection.
- Item 1. Formula I: (In the formula, R 1 represents a linear or branched acyl group having 14 to 24 carbon atoms. R 2 represents OH, NH 2 , NR 3 R 4 , a substituted or unsubstituted alkoxy group, a substituted or unsubstituted group.
- Item 3. Item 2. The self-assembly according to Item 1, wherein R 2 represents OH or NH 2 .
- Item 4. Item 2. The self-assembly according to Item 1, wherein R 1 represents a stearoyl group and R 2 represents OH or NH 2 .
- Item 6. Item 6.
- a preventive or therapeutic agent for an influenza virus infection comprising the self-assembly according to any one of Items 1 to 5.
- Item 7. Item 7. The prophylactic or therapeutic agent according to Item 6, wherein the influenza virus is H1 subtype, H3 subtype, H5 subtype or H7 subtype.
- Item 8. Item 7. The preventive or therapeutic agent according to Item 6, wherein the influenza virus is an H1 subtype or H3 subtype influenza virus.
- Item 10. Formula I: (In the formula, R 1 represents a stearoyl group and R 2 represents NH 2. ) Or a pharmaceutically acceptable salt thereof, or a self-assembly thereof.
- R 1 represents a linear or branched acyl group having 14 to 24 carbon atoms.
- R 2 represents OH, NH 2 , NR 3 R 4 , a substituted or unsubstituted alkoxy group, a substituted or unsubstituted group.
- a powerful preventive or therapeutic agent for influenza / influenza virus infection can be obtained.
- the peptide of SEQ ID NO: 2 has a strong effect in vitro, but has no effect in vivo, but rather has an effect of exacerbating influenza virus infection.
- the N-acylated peptide of the formula (I) of the present invention (particularly the peptide of SEQ ID NO: 2) not only has a strong effect in vitro, but also has a preventive or therapeutic effect against a strong influenza virus in vivo. .
- C18D1 (stearoyl-GLAMAPSVGHVRQHG-NH 2 ) has a very low IC 50 of about 500 ⁇ M against H1 and H3 influenza viruses when incorporated into liposomes, and has virtually no anti-influenza virus effect, but self-assembly It has a very strong effect on the body.
- C18-D1 C18-GLAMAPSVGHVRQHG-NH2
- C18-S2 C18-ARLPRTMVHPKPAQP-NH2
- the peptide dosage is C18-D1 (17.4 mg / kg), C18-S2 (19.4 mg / kg).
- a self-assembly of the following compound of formula I or a pharmaceutically acceptable salt thereof can be used as a preventive or therapeutic agent for influenza virus infection.
- R 1 represents a linear or branched acyl group having 14 to 24 carbon atoms.
- R 2 represents OH, NH 2 , NR 3 R 4 , a substituted or unsubstituted alkoxy group, a substituted or unsubstituted group.
- the compound of the present invention not only enhances the preventive or therapeutic action of influenza virus infection by using the compound of formula I as a self-assembly, but also includes H1 subtype (eg H1N1, H1N2), H3 subtype (eg H3N2 ), H5 subtype (eg H5N1 type), H7 subtype (eg H7N1 type), and the effectiveness against a wide range of influenza viruses can be obtained.
- H1 subtype eg H1N1, H1N2
- H3 subtype eg H3N2
- H5 subtype eg H5N1 type
- H7 subtype eg H7N1 type
- the self-assembly of the present invention has been demonstrated to be effective for the H1 subtype and the H3 subtype as shown in the examples.
- the self-assembly of compounds of formula I is effective for both H1 and H3 subtypes, and thus is relatively unmutated between hemagglutinin subtypes and is well-preserved in its three-dimensional structure. It is thought that the anti-influenza virus action is expressed by binding to the receptor binding pocket region. Therefore, the self-assembly of the compound of formula I of the present invention is not only against influenza virus H1 and H3 subtypes, but also against infections of H5 and H7 subtypes that share the receptor binding pocket region. Is also effective.
- the self-assembly of the present invention is effective not only in vitro but also in vivo.
- S2 ARLPRTMVHPKPAQP-NH 2
- N-terminal was stearoylated C18-S2
- stearoyl -ARLPRTMVHPKPAQP-NH 2 has the strong anti-influenza virus effect in vitro, as well as not effective in vivo influenza virus Has a tendency to accelerate death from infection.
- the anti-influenza virus action is greatly different between in vivo and in vitro, and it is one of the characteristics that the peptide of the present invention has an anti-influenza virus action not only in vitro but also in vivo.
- the self-assembly of the present invention has a micelle-like structure in which the acyl group represented by R 1 faces inward and the peptide part faces outward.
- phospholipid is the main component.
- Self-assembly of the compound of formula I cannot be formed due to the formation of the elemental liposomes.
- Patent Document 1 what is obtained in the examples of Patent Document 1 is a stearoyl N-terminal stearoylated (C18) peptide whose C-terminus is a carboxyl group (COOH), and stearoyl of the present application whose C-terminus is an amide (CONH2). Peptides are not disclosed.
- Patent Document 1 discloses only the production of a compound of formula I in which R 1 is a stearoyl group and R 2 is OH, and its liposome preparation, and no self-assembly is obtained.
- Patent Document 1 states that the liposome formulation of the compound of formula I is effective only for the H3 subtype (H3N2) and not for the H1 subtype (H1N1).
- H3N2 H3 subtype
- H1N1 H1 subtype
- the inventor believes that the effect of the self-assembly of the compounds of formula I of the present invention on a wide range of influenza viruses is due to the structure of the self-assembly.
- a self-assembly of the compound of formula I can be prepared by dissolving the compound of formula I in water and stirring as necessary.
- a self-assembly can be produced by dissolving the compound in water. As the concentration of the compound of formula I increases, the average particle size of the self-assembly tends to increase.
- the average particle size of the self-assembly of the compound of formula I should be about 100 nm or more, for example, about 100 nm to about 20 ⁇ m, preferably about 300 nm to about 10 ⁇ m, more preferably about 500 nm to about 7 ⁇ m, Particularly preferred is about 700 nm to about 5 ⁇ m.
- the self-assembly may be obtained by dissolving in water, that is, in a state dispersed in water, and is easily self-assembled when it comes into contact with water like a lyophilized product. Widely includes those that reproduce.
- the acyl group is a straight chain or branched chain having 14 to 24 carbon atoms and may be substituted with a hydroxyl group, such as a myristoyl group, a palmitoyl group, a stearoyl group, an araquinoyl group, a behenoyl group.
- Lignocelloyl group myristooleoyl group, palmitooleoyl group, oleoyl group, linoleoyl group, ⁇ -linolenoyl group, ⁇ -linolenoyl group, arachidyl group, elidoyl group, eicosatrienoyl group, isostearoyl group, 12-hydroxystearoyl group And lisinole oil group.
- R 1 groups have a corresponding linear or branched group having 14 to 24 carbon atoms, preferably 16 to 22 carbon atoms, more preferably 16 to 20 carbon atoms, and particularly 18 to 20 carbon atoms, and are substituted with a hydroxyl group.
- the carbon number of R 1 exceeds 20, the water solubility of the obtained peptide decreases, so the carbon number of R 1 is preferably 16-20, particularly 18-20.
- examples of the alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like, preferably 1 to 6 carbon atoms.
- substituent for the alkyl group include a hydroxyl group, a fluorine atom, a methoxy group, and an ethoxy group.
- aryl group examples include phenyl, naphthyl, fluorenyl, anthryl, biphenylyl, tetrahydronaphthyl, chromanyl, 2,3-dihydro-1,4-dioxanaphthalenyl, indanyl and phenanthryl.
- aralkyl group examples include benzyl, naphthylmethyl, fluorenylmethyl, anthrylmethyl, biphenylylmethyl, tetrahydronaphthylmethyl, chromanylmethyl, 2,3-dihydro-1,4-dioxanaphthalenylmethyl.
- Indanylmethyl and phenanthrylmethyl phenethyl, naphthylethyl, fluorenylethyl, anthrylethyl, biphenylylethyl, tetrahydronaphthylethyl, chromanylethyl, 2,3-dihydro-1,4-dioxanaphthale
- Examples include nylethyl, indanylethyl and phenanthrylethyl.
- Alkoxy groups include O- (alkyl), where alkyl is as defined above.
- substituent for the alkoxy group include a hydroxyl group, a fluorine atom, a methoxy group, and an ethoxy group.
- Aryloxy includes O- (aryl), where aryl is as defined above.
- Aralkyloxy includes O- (aralkyl), where aralkyl is as defined above.
- substituent for the alkyl group examples include a fluorine atom, an alkoxy group, cyano, and hydroxy.
- Aryl groups such as aryl groups, aralkyl groups, and aryloxy groups
- substituents of aralkyl moieties include halogen atoms (F, Cl, Br, I), nitro, amino, monoalkylamino, dialkylamino
- Examples include acetyl, methylenedioxy, alkyl, alkoxy, carbamoyl, acetylamino and the like, and the number of substituents is 1 to 5, preferably 1 to 3, and more preferably 1 to 2.
- R 2 is preferably OH, NH 2 , NR 3 R 4 (R 3 and R 4 are as defined above), or alkoxy.
- Ala Pro Ser Val Gly His Val Arg Gln His Gly-R 2 and can be obtained by introducing the acyl group of R 1 using a coupling reagent such as DIC.
- the R 2 group can be introduced by using Gly-R 2 as the C-terminal amino acid.
- the R 2 group can be cleaved out as an OH or NH 2 peptide by selection of a carrier for solid phase synthesis.
- pharmaceutically acceptable salts of the compound of formula I include inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, trifluoroacetic acid, acetic acid, maleic acid, fumaric acid, Examples thereof include organic acid salts such as malic acid, tartaric acid, methanesulfonic acid and toluenesulfonic acid, and alkali metal or alkaline earth metal salts such as sodium salt, potassium salt, lithium salt, calcium salt and magnesium salt.
- inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, trifluoroacetic acid, acetic acid, maleic acid, fumaric acid
- organic acid salts such as malic acid, tartaric acid, methanesulfonic acid and toluenesulfonic acid
- alkali metal or alkaline earth metal salts such as sodium salt, potassium salt, lithium salt, calcium salt and magnesium
- the self-assembly of the present invention is infected with influenza virus as a pharmaceutical preparation containing the self-assembly of the present invention as an active ingredient and a pharmaceutically acceptable carrier, diluent, and excipient as optional ingredients. It can be administered to mammals including humans before infection, birds and the like.
- the administration method of the prophylactic / therapeutic agent for influenza virus infection of the present invention is not particularly limited, and is appropriately determined according to various preparation forms, patient age, sex, other conditions, severity of disease, and the like.
- Preferred examples of the dosage form include parenteral dosage forms such as tablets, capsules, granules, sublingual tablets, etc., injections, drops, nasal drops, inhalants, patches, cataplasms, etc. Can do. Inhalants are particularly preferred.
- the daily dose of the self-assembly of the compound of formula I which is an active ingredient of the preventive or therapeutic agent (including pharmaceutical compositions and pharmaceutical preparations) of influenza of the present invention is the symptom, body weight, age, sex, etc. of the subject. Although it varies depending on the situation and cannot be determined in general, it can usually be selected from the range of about 0.001 to 100 mg per day for an adult.
- the influenza preventive or therapeutic agent is not limited to once daily administration, and can be administered in several divided doses.
- D1 is represented by SEQ ID NO: 1 and S2 is represented by SEQ ID NO: 2.
- Example 1 The critical micelle concentration (CMC) of purified C18-D1 was measured as follows. PBS (pH 7.5) containing 1 ⁇ M N-phenyl-1-naphthylamine (hereinafter abbreviated as ⁇ NPN '') was prepared, and a peptide stock solution of C18-D1 (1 mM) was added at a final concentration of 0.1, 0.3, 1.3, Serial dilution was performed at 10, 30 ⁇ M. These solutions were excited at a wavelength of 350 nm, and the fluorescence intensity (FI) at 450 nm was measured. The difference in FI from the case of PBS alone was plotted on the vertical axis and the peptide solution on the horizontal axis, and the concentration at the intersection of high and low concentration lines was determined. The intersection concentration (CMC) was 1.3 ⁇ M.
- ⁇ NPN '' N-phenyl-1-naphthylamine
- Example 2 In vitro test of influenza infection inhibition Inhibition of influenza virus infection was determined by plaque assay on MDCK cells.
- MDCK cells in 6-well plates contain influenza A / PR / 8/8 containing C18-D1, S2 (H-ARLPRTMVHPKPAQP-NH2), C18-S2 (stearoyl-ARLPRTMVHPKPAQP-NH2), D1 (H-GLAMAPSVGHVRQHG-NH2). It was incubated with 0.2 mL of 34 virus solution (100-200 pfu, pfu is plaque forming unit, H1N1 type) or influenza A / Victoria / 1/75 virus solution (100-200 pfu, H3N2 type). After incubation at 37 ° C.
- C18-D1 In-vitro inhibition by C18-D1 of influenza virus infection of MDCK cells was determined by plaque assay. In the presence of C18-D1 (C18-D1), influenza A virus HA1 (A / PR / 8/34 (H1N1)), influenza A virus HA3 (A / Victoria / 1/75 (H3N2) on MDCK cells )) Infection was inhibited.
- Example 3 Animal Test for Inhibition of Influenza Infection Virus infection inhibition experiments were carried out on C18-D1 and C18-S2 mice of the present invention.
- a peptide stock solution (2.5-7.5 mM in PBS) and PBS (200 pfu) containing influenza virus (H1N1) were mixed in the following volume and left at room temperature for 30 minutes.
- the prepared samples were administered one by one into the nasal cavity of mice.
- C18-D1 had infection-inhibiting activity, and mice survived 80% or more (FIG. 1).
- C18-S2 which has an activity equivalent to or higher than C18-D1 in the in vitro test, resulted in earlier death in the in vivo test compared to the control.
- mice died after sputum virus alone (mPR8).
- mPR8 means a control in which influenza virus and PBS are mixed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
項1.式I:
(式中、R1は炭素数14~24の直鎖又は分岐を有するアシル基を示す。R2はOH、NH2、NR3R4、置換または非置換のアルコキシ基、置換または非置換のアリールオキシ基、置換または非置換のアラルキルオキシ基を示す。R3,R4は同一または異なって、置換または非置換のアルキル基、置換または非置換のアリール基、置換または非置換のアラルキル基、アルコキシ基、水酸基が挙げられる。ただし、R3とR4は同時に水酸基、アルコキシ基となることはない。)
で示される化合物又はその薬学的に許容される塩の自己集合体。
項2.R1はステアロイル基、パルミトイル基、オレオイル基またはパルミトオレオイル基を示す、項1に記載の自己集合体。
項3.R2はOHまたはNH2を示す、項1に記載の自己集合体。
項4.R1はステアロイル基を示し、R2はOHまたはNH2を示す、項1に記載の自己集合体。
項5.前記自己集合体が凍結乾燥物の形態である、項1~4のいずれかに記載の自己集合体。
項6.項1~5のいずれかに記載の自己集合体を含むインフルエンザウイルスの感染症の予防又は治療剤。
項7.インフルエンザウイルスがH1亜型、H3亜型、H5亜型またはH7亜型である、項6に記載の予防又は治療剤。
項8.インフルエンザウイルスがH1亜型またはH3亜型インフルエンザウイルスである、項6に記載の予防又は治療剤。
項9.インフルエンザウイルスがH1亜型インフルエンザウイルスである、項6に記載の予防又は治療剤。
項10.式I:
(式中、R1はステアロイル基を示し、R2はNH2を示す。)
で示される化合物又はその薬学的に許容される塩、もしくはその自己集合体。
項11.式I:
(式中、R1は炭素数14~24の直鎖又は分岐を有するアシル基を示す。R2はOH、NH2、NR3R4、置換または非置換のアルコキシ基、置換または非置換のアリールオキシ基、置換または非置換のアラルキルオキシ基を示す。R3,R4は同一または異なって、置換または非置換のアルキル基、置換または非置換のアリール基、置換または非置換のアラルキル基、アルコキシ基、水酸基が挙げられる。ただし、R3とR4は同時に水酸基、アルコキシ基となることはない。)
で示される化合物又はその薬学的に許容される塩もしくはその自己集合体の有効量をインフルエンザウイルスに感染した患者もしくは感染する可能性のある被験体に投与することを包含する、インフルエンザウイルス感染症の予防又は治療方法。
(式中、R1は炭素数14~24の直鎖又は分岐を有するアシル基を示す。R2はOH、NH2、NR3R4、置換または非置換のアルコキシ基、置換または非置換のアリールオキシ基、置換または非置換のアラルキルオキシ基を示す。R3,R4は同一または異なって、置換または非置換のアルキル基、置換または非置換のアリール基、置換または非置換のアラルキル基、アルコキシ基、水酸基が挙げられる。ただし、R3とR4は同時に水酸基、アルコキシ基となることはない。)
Fmoc法に従い、Fmocアミノ酸(1.4当量)とHOBt(1-ヒドロキシベンゾトリアゾール;2.5当量)、DIC(2.8当量)を用い、固相合成によりH-Gly Leu Ala Met Ala Pro Ser Val Gly His Val Arg Gln His Gly-NH2で表されるポリペプチドを合成した。得られたポリペプチドを、ペプチド合成と同様な条件下でステアリン酸(1当量)、DIC(2.8当量)、HOBt(2.5当量)を用い、DMF/DCM溶媒中で90分間反応させて、N末端のアミノ基にステアロイル基が結合した本発明の(ステアロイル)-Gly Leu Ala Met Ala Pro Ser Val Gly His Val Arg Gln His Gly-NH2で表されるポリペプチド(以下、「C18-D1」もしくは「C18-D1」とする)を合成した。精製は、C-18カラムを使用するHPLCにより行った。C18-D1が得られたことは、質量分析([M+H]+=1782.29)により確認した。
参考例1と同様にして、C18-S2(ステアロイル-ARLPRTMVHPKPAQP-NH2)、S2(ARLPRTMVHPKPAQP-NH2)、D1(GLAMAPSVGHVRQHG-NH2)を合成した。C18-S2、S2、D1が得られたことは、質量分析により確認した。
精製したC18-D1の臨界ミセル濃度(CMC)を以下のように測定した。
1μMのN-フェニル-1-ナフチルアミン(以下「NPN」と略記する)を含むPBS (pH7.5)を調製し、C18-D1のペプチドストック溶液(1 mM)を終濃度0.1, 0.3, 1.3, 10, 30 μMで系列希釈した。これらの溶液を波長350 nmで励起し、450 nmの蛍光強度(FI)を測定した。PBSのみの場合とのFIの差を縦軸に、ペプチド溶液を横軸にプロットし、高濃度および低濃度の直線の交点の時の濃度を求めた。交点の濃度(CMC)は1.3μMであった。
インフルエンザウイルスの感染の阻害をMDCK細胞上のプラークアッセイにより決定した。6ウェルプレート中のMDCK細胞は、C18-D1、S2(H-ARLPRTMVHPKPAQP-NH2)、C18-S2(ステアロイル-ARLPRTMVHPKPAQP-NH2)、D1(H-GLAMAPSVGHVRQHG-NH2)を含むインフルエンザA/PR/8/34ウイルス溶液(100-200pfu、pfuとはプラーク形成ユニット、H1N1型)0.2mL、もしくはインフルエンザA/Victria/1/75ウイルス溶液(100-200pfu、H3N2型)とインキュベートした。5%のCO2の下での37℃、30分間のインキュベーションの後、上清を除去し、細胞をPBSを用いて洗浄した。0.6%のアガロース(0.01%のO-ジエチルアミノエチルセルロースデキストラン、0.1%NaHCO3、0.01μg/mLアセチルトリプシンを含む2×MEM+BSA 2mL(1つのウェル当たり)を添加し、2日間インキュベートした。生細胞をクリスタルバイオレット溶液(20%のエタノール中1mg/mL)で染色し、プラークの数をカウントした。最高感染活性(100%)はC18-D1のない場合のプラークの数として定義した。C18-D1のIC50値(50%抑制濃度)は、log[f/(1-f)]とlog[C18-D1]、ここでfは感染活性割合である、の間のプロットから得られた。S2、C18-S2、D1のIC50値も同様に算出した。
本発明のC18-D1およびC18-S2のマウスに対するウイルスの感染阻害実験を行った。ペプチドストック溶液(2.5-7.5mM in PBS)とインフルエンザウイルス(H1N1)を含むPBS(200 pfu)を以下の容量で混合し、30分室温放置した。作製したサンプルを一匹ずつマウスの鼻腔内に50μLずつ投与した。
Claims (11)
- R1はステアロイル基、パルミトイル基、オレオイル基またはパルミトオレオイル基を示す、請求項1に記載の自己集合体。
- R2はOHまたはNH2を示す、請求項1に記載の自己集合体。
- R1はステアロイル基を示し、R2はOHまたはNH2を示す、請求項1に記載の自己集合体。
- 前記自己集合体が凍結乾燥物の形態である、請求項1~4のいずれかに記載の自己集合体。
- 請求項1~5のいずれかに記載の自己集合体を含むインフルエンザウイルスの感染症の予防又は治療剤。
- インフルエンザウイルスがH1亜型、H3亜型、H5亜型またはH7亜型である、請求項6に記載の予防又は治療剤。
- インフルエンザウイルスがH1亜型またはH3亜型インフルエンザウイルスである、請求項6に記載の予防又は治療剤。
- インフルエンザウイルスがH1亜型インフルエンザウイルスである、請求項6に記載の予防又は治療剤。
- 式I:
(式中、R1は炭素数14~24の直鎖又は分岐を有するアシル基を示す。R2はOH、NH2、NR3R4、置換または非置換のアルコキシ基、置換または非置換のアリールオキシ基、置換または非置換のアラルキルオキシ基を示す。R3,R4は同一または異なって、置換または非置換のアルキル基、置換または非置換のアリール基、置換または非置換のアラルキル基、アルコキシ基、水酸基が挙げられる。ただし、R3とR4は同時に水酸基、アルコキシ基となることはない。)
で示される化合物又はその薬学的に許容される塩もしくはその自己集合体の有効量をインフルエンザウイルスに感染した患者もしくは感染する可能性のある被験体に投与することを包含する、インフルエンザウイルス感染症の予防又は治療方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/061,370 US20110152178A1 (en) | 2008-08-29 | 2009-08-07 | Prophylactic or therapeutic agent for influenza virus infection |
EP09809762A EP2327714A4 (en) | 2008-08-29 | 2009-08-07 | PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST FLUID VIRUS INFECTION |
CN2009801339180A CN102137868A (zh) | 2008-08-29 | 2009-08-07 | 用于流感病毒感染的预防或治疗剂 |
JP2010526641A JP5583017B2 (ja) | 2008-08-29 | 2009-08-07 | インフルエンザウイルス感染症の予防ないし治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-222062 | 2008-08-29 | ||
JP2008222062 | 2008-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010024108A1 true WO2010024108A1 (ja) | 2010-03-04 |
Family
ID=41721280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/064012 WO2010024108A1 (ja) | 2008-08-29 | 2009-08-07 | インフルエンザウイルス感染症の予防ないし治療剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110152178A1 (ja) |
EP (1) | EP2327714A4 (ja) |
JP (1) | JP5583017B2 (ja) |
CN (1) | CN102137868A (ja) |
WO (1) | WO2010024108A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012018907A3 (en) * | 2010-08-03 | 2012-05-10 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
US9602707B2 (en) | 2007-05-29 | 2017-03-21 | Lab Partners Associates, Inc. | External photographic wireless communication device |
US9918000B2 (en) | 2005-07-20 | 2018-03-13 | Lab Partners Associates, Inc. | Zero delay predictor signal synchronization system and method |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2800576A2 (en) * | 2012-03-13 | 2014-11-12 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
WO2015143339A2 (en) | 2014-03-21 | 2015-09-24 | University Of Washington | Enhanced influenza hemagglutinin binders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000059932A1 (fr) * | 1999-03-31 | 2000-10-12 | Otsuka Pharmaceutical Co., Ltd. | Peptides se liant a l'hemagglutinine du virus de la grippe |
JP2002284798A (ja) | 2001-03-27 | 2002-10-03 | Keio Gijuku | インフルエンザウイルス・ヘマグルチニン結合性ペプチド |
WO2005084694A1 (ja) * | 2004-03-09 | 2005-09-15 | Glycomedics, Inc. | インフルエンザウイルス感染抑制剤 |
JP2006101709A (ja) | 2004-09-30 | 2006-04-20 | Glycomedics Inc | ヘマグルチニン結合ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ治療薬、インフルエンザ予防薬 |
JP2007145777A (ja) * | 2005-11-29 | 2007-06-14 | Glycomedics Inc | インフルエンザウイルス感染阻害方法 |
WO2007105565A1 (ja) * | 2006-03-13 | 2007-09-20 | Keio University | インフルエンザ感染阻害ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤 |
-
2009
- 2009-08-07 WO PCT/JP2009/064012 patent/WO2010024108A1/ja active Application Filing
- 2009-08-07 JP JP2010526641A patent/JP5583017B2/ja active Active
- 2009-08-07 EP EP09809762A patent/EP2327714A4/en not_active Withdrawn
- 2009-08-07 US US13/061,370 patent/US20110152178A1/en not_active Abandoned
- 2009-08-07 CN CN2009801339180A patent/CN102137868A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000059932A1 (fr) * | 1999-03-31 | 2000-10-12 | Otsuka Pharmaceutical Co., Ltd. | Peptides se liant a l'hemagglutinine du virus de la grippe |
JP2002284798A (ja) | 2001-03-27 | 2002-10-03 | Keio Gijuku | インフルエンザウイルス・ヘマグルチニン結合性ペプチド |
WO2005084694A1 (ja) * | 2004-03-09 | 2005-09-15 | Glycomedics, Inc. | インフルエンザウイルス感染抑制剤 |
JP2006101709A (ja) | 2004-09-30 | 2006-04-20 | Glycomedics Inc | ヘマグルチニン結合ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ治療薬、インフルエンザ予防薬 |
JP2007145777A (ja) * | 2005-11-29 | 2007-06-14 | Glycomedics Inc | インフルエンザウイルス感染阻害方法 |
WO2007105565A1 (ja) * | 2006-03-13 | 2007-09-20 | Keio University | インフルエンザ感染阻害ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤 |
Non-Patent Citations (8)
Title |
---|
MATSUBARA, T. ET AL.: "Inhibition of Influenza Virus Infections by Sialylgalactose-Binding Peptides Selected from a Phage Library.", J. MED. CHEM., vol. 52, no. 14, July 2009 (2009-07-01), pages 4247 - 4256, XP008144210 * |
SATO, T. ET AL.: "Inhibition of Influenza Virus Infection by Hemagglutinin-Binding Peptides.", PEPT. SCI., vol. 38, 2002, pages 329 - 330, XP003017756 * |
See also references of EP2327714A4 * |
SHOKO CHIBA ET AL.: "Influenza Virus Kansen Sogai Peptide no Kassei o Kojo suru Kagaku Shushoku", CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, vol. 89, no. 2, March 2009 (2009-03-01), pages 1291, XP008144202 * |
TERUHIKO MATSUBARA ET AL.: "Hemagglutinin Ketsugosei Peptide no Kaihen Oyobi Tansaka ni yoru Influenza Virus Kansen Sogai Kassei no Kojo", SYMPOSIUM ON POLYMERS AND BIOSCIENCES KOEN YOSHISHU, vol. 18, - July 2008 (2008-07-01), pages 81 - 82, XP008144199 * |
TERUHIKO MATSUBARA ET AL.: "Saibo Hyomen no Sial-san, Gan'yu Tosa o Hyoteki to suru Peptide no Sekkei Oyobi Kino Kaiseki", POLYMER PREPRINTS, JAPAN, vol. 57, no. 2, September 2008 (2008-09-01), pages 4801 - 4802, XP008144203 * |
TERUHIKO MATSUBARA ET AL.: "Sialyloligo-to Ketsugosei Peptide no Influenza Virus Kansen Sogai Kassei", POLYMER PREPRINTS, JAPAN, vol. 57, no. 1, May 2008 (2008-05-01), pages 1703, XP008144200 * |
Y. SUZUKI, PROG. LIPID. RES., vol. 33, 1994, pages 429 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9918000B2 (en) | 2005-07-20 | 2018-03-13 | Lab Partners Associates, Inc. | Zero delay predictor signal synchronization system and method |
US9602707B2 (en) | 2007-05-29 | 2017-03-21 | Lab Partners Associates, Inc. | External photographic wireless communication device |
WO2012018907A3 (en) * | 2010-08-03 | 2012-05-10 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
US8765686B2 (en) | 2010-08-03 | 2014-07-01 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
US9181300B2 (en) | 2010-08-03 | 2015-11-10 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
Also Published As
Publication number | Publication date |
---|---|
CN102137868A (zh) | 2011-07-27 |
EP2327714A4 (en) | 2012-04-25 |
US20110152178A1 (en) | 2011-06-23 |
EP2327714A1 (en) | 2011-06-01 |
JPWO2010024108A1 (ja) | 2012-01-26 |
JP5583017B2 (ja) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021046436A (ja) | ペプチド模倣大環状分子およびその製剤 | |
JP6615755B2 (ja) | インフルエンザウイルスの複製の阻害剤 | |
EP2376100B1 (en) | Peptidomimetic macrocycles | |
JP5093100B2 (ja) | インフルエンザ感染阻害ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤 | |
JP5583017B2 (ja) | インフルエンザウイルス感染症の予防ないし治療剤 | |
JP5764621B2 (ja) | インフルエンザを阻害する組成物および方法 | |
JP2021511370A (ja) | 急性ウイルス性呼吸器疾患を治療するための経鼻医薬組成物 | |
WO2000059932A1 (fr) | Peptides se liant a l'hemagglutinine du virus de la grippe | |
JP2002284798A (ja) | インフルエンザウイルス・ヘマグルチニン結合性ペプチド | |
Yang et al. | Influenza virus entry inhibitors | |
JP6910043B2 (ja) | ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬 | |
US9221874B2 (en) | Antiviral peptides against influenza virus | |
EP3210995B1 (en) | Hemagglutinin-binding peptide | |
AU2016359545A1 (en) | Peptides and uses therefor as antiviral agents | |
CN108822190B (zh) | 多肽及其药物组合物和用途 | |
JP2006101709A (ja) | ヘマグルチニン結合ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ治療薬、インフルエンザ予防薬 | |
TWI429426B (zh) | 4,5-雙胺基-3-鹵基-2-羥基苯甲酸衍生物、製法及其用途 | |
JP2023527305A (ja) | Sars-cov-2ウイルス感染を阻害するための組成物及び方法 | |
JP2020033325A (ja) | 抗インフルエンザウイルス活性ペプチドおよびインフルエンザウイルス感染症の予防・治療薬 | |
WO2018199798A1 (ru) | Пептидные производные противовирусного препарата занамивира | |
EA033921B1 (ru) | Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа | |
JP2017128544A (ja) | インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤 | |
WO2005082394A1 (ja) | インスリン受容体のリン酸化阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980133918.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09809762 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2010526641 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13061370 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009809762 Country of ref document: EP |